Clinical trial · Interventional
Diagnostic Value of Next-Generation Sequencing Analysis in Biliary Tract Tumours
NCT06729944CI-TRIAL-00083681recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to identify a dysplasia- and CCA-specific NGS panel to increase the diagnostic sensitivity of histological and/or cytological examination of biliary tract stenosis.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatectomy | — | UNRESOLVED | — |
| NGS | — | UNRESOLVED | — |
| Stenosis of Bile Duct | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| NGS | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Patients undergoing biliary tract resection
- description
- Patients undergoing biliary tract resection, as part of the normal care pathway, will be enrolled
- interventionNames
- Diagnostic Test: NGS
Primary outcomes (1)
- measure
- Identification of an NGS panel specific to dysplasia and CCA
- timeFrame
- During enrollment period, up to 30 months
- description
- Ratio between the number of cases identified with NGS panel and the number of cases identified with standard of care
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Availability of enough tissue for histological and NGS analysis (at least 20 ng DNA). * Age greater than/equal to 18 years. Exclusion Criteria: * None
References
Publications (0)
Data not yet available
No reference posted for this study.